{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T10:39:29Z","timestamp":1784371169966,"version":"3.55.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\"><jats:title>Background<\/jats:title><jats:p>Actovegin is a hemodialysate of calf\u2019s blood and has been used for several decades in the countries of Central Asia, East Asia, Russia and some European countries. It has been used to treat patients with various neurological conditions, vascular disorders, and ischemic stroke.<\/jats:p><\/jats:sec><jats:sec id=\"sec002\"><jats:title>Objectives<\/jats:title><jats:p>To perform a systematic review to evaluate the effect of Actovegin in patients who have suffered an ischemic stroke.<\/jats:p><\/jats:sec><jats:sec id=\"sec003\"><jats:title>Methods<\/jats:title><jats:p>A search of MEDLINE, PubMed, Cochrane and Embase was carried out from inception to October 10, 2021 for clinical trials and observational studies with a control group, published in English or Russian.<\/jats:p><\/jats:sec><jats:sec id=\"sec004\"><jats:title>Results<\/jats:title><jats:p>Of 220 identified unique records, 84 full-text articles were screened, and 5 studies were selected that met the inclusion criteria. This included 4 observational studies with control groups and one randomized, placebo-controlled clinical trial. These studies enrolled a total of 3879 patients of which 720 patients received Actovegin administered intravenously and\/or orally for a duration ranging from 10 to 180 days. Because of study heterogeneity, meta-analysis was not performed. No consistent evidence on improved survival, quality of life, neurologic symptoms, activities of daily living or disability was identified. One study showed statistically significant improvements in the Alzheimer\u2019s Disease Assessment Scale, cognitive subscale, extended version (ADAS-cog+) for Actovegin compared with placebo at 6 months but the clinical relevance of this change is uncertain. One study reported a higher incidence of recurrent ischemic stroke, transient ischemic attack or intracerebral hemorrhage in patients taking Actovegin compared to placebo.<\/jats:p><\/jats:sec><jats:sec id=\"sec005\"><jats:title>Conclusions<\/jats:title><jats:p>The benefits of Actovegin are uncertain and that there is potential risk of harm in patients with stroke. More evidence is needed from rigorously designed clinical trials to justify the role of Actovegin in patients with ischemic stroke.<\/jats:p><\/jats:sec>","DOI":"10.1371\/journal.pone.0270497","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T17:46:22Z","timestamp":1656611182000},"page":"e0270497","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Actovegin in the management of patients after ischemic stroke: A systematic review"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8478-1550","authenticated-orcid":true,"given":"Philip","family":"la Fleur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0956-6743","authenticated-orcid":true,"given":"Ardak","family":"Baizhaxynova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Reynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Kaunelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinara","family":"Galiyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"issue":"5","key":"pone.0270497.ref001","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","article-title":"Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"GBD Neurology Collaborators","year":"2019","journal-title":"Lancet Neurol"},{"issue":"25","key":"pone.0270497.ref002","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1804492","article-title":"Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016","volume":"379","author":"GBD 2016 Lifetime Risk of Stroke Collaborators","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0270497.ref003","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000441085","article-title":"Update on the global burden of ischemic and hemorrhagic stroke in 1990\u20132013: the GBD 2013 study","volume":"45","author":"VL Feigin","year":"2015","journal-title":"Neuroepidemiology"},{"key":"pone.0270497.ref004","unstructured":"Canadian stroke best practices [Internet]. Ottawa (ON): Heart and Stroke Foundation of Canada; 2018. [cited 3 November 2021]. Available from: https:\/\/www.strokebestpractices.ca."},{"issue":"2","key":"pone.0270497.ref005","first-page":"260","article-title":"Epidemiology and primary prevention of stroke","volume":"26","author":"K Furie","year":"2020","journal-title":"Continuum (Minneap Minn)."},{"issue":"2","key":"pone.0270497.ref006","first-page":"435","article-title":"Medical management for secondary stroke prevention","volume":"26","author":"AS Kim","year":"2020","journal-title":"Continuum (Minneap Minn)."},{"issue":"1\u20132","key":"pone.0270497.ref007","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jns.2012.07.069","article-title":"Pleiotropic neuroprotective and metabolic effects of Actovegin\u2019s mode of action","volume":"322","author":"F Machicao","year":"2012","journal-title":"J Neurol Sci"},{"key":"pone.0270497.ref008","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1134\/S0012496613010055","article-title":"Actovegin reduces the ROS level in blood samples of heart failure patients and diminishes necrosis of SK-N-SH human neuroblastoma cells","volume":"448","author":"EI Astashkin","year":"2013","journal-title":"Dokl Biol Sci"},{"issue":"1","key":"pone.0270497.ref009","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/JSM.0000000000000566","article-title":"Update on the role of Actovegin in musculoskeletal medicine: a review of the past 10 years","volume":"30","author":"J Brock","year":"2020","journal-title":"Clin J Sport Med"},{"issue":"4","key":"pone.0270497.ref010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12017-011-8157-7","article-title":"Neuroprotective and anti-oxidative effects of the hemodialysate Actovegin on primary rat neurons in vitro.","volume":"13","author":"MW Elmlinger","year":"2011","journal-title":"Neuromolecular Med."},{"issue":"1","key":"pone.0270497.ref011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1134\/S0012496614030132","article-title":"Actovegin reduces the hydrogen peroxide-induced cell apoptosis of SK-N-SH neuroblastoma by means of p38MAPK and PI-3K inhibition","volume":"456","author":"MM Yurinskaya","year":"2014","journal-title":"Dokl Biol Sci"},{"issue":"3\u20134","key":"pone.0270497.ref012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10354-011-0865-y","article-title":"Actovegin\u00ae: a biological drug for more than 5 decades","volume":"161","author":"F Buchmayer","year":"2011","journal-title":"Wien Med Wochenschr"},{"issue":"5","key":"pone.0270497.ref013","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1161\/STROKEAHA.116.014321","article-title":"ARTEMIDA Trial (A Randomized Trial of Efficacy, 12 Months International Double-Blind Actovegin): a randomized controlled trial to assess the efficacy of Actovegin in poststroke cognitive impairment","volume":"48","author":"A Guekht","year":"2017","journal-title":"Stroke"},{"key":"pone.0270497.ref014","unstructured":"Clinicaltrials.gov. Actovegin search results. Bethesda (MD): National Library of Medicine (US). [Internet].[cited 26 November 2021]. Available from: https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=actovegin."},{"issue":"9","key":"pone.0270497.ref015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093181","article-title":"Current synthesis and systematic review of main effects of calf blood deproteinized medicine (Actovegin(\u00ae)) in ischemic stroke","volume":"21","author":"FC Firan","year":"2020","journal-title":"Int J Mol Sci"},{"key":"pone.0270497.ref016","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.mehy.2017.09.029","article-title":"Calf hemodialysate hypothesis: nutritive value plus placebo effect","volume":"109","author":"SV Jargin","year":"2017","journal-title":"Med Hypotheses"},{"issue":"1\u20132","key":"pone.0270497.ref017","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jns.2012.02.013","article-title":"Neuroprotection in vascular dementia: a future path","volume":"322","author":"I Skoog","year":"2012","journal-title":"J Neurol Sci"},{"issue":"1","key":"pone.0270497.ref018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"AR Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"pone.0270497.ref019","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"key":"pone.0270497.ref020","author":"G Wells","year":"2021"},{"issue":"8","key":"pone.0270497.ref021","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11055-008-9051-0","article-title":"Experience in the use of Actovegin in the treatment of patients with cognitive disorders in the acute period of stroke","volume":"38","author":"EA Derev\u2019yannykh","year":"2008","journal-title":"Neurosci Behav Physiol"},{"issue":"8","key":"pone.0270497.ref022","article-title":"Clinical and prognostic aspects of using Actovegin in the acute period of ischemic stroke","volume":"111","author":"V. Ershov","year":"2011","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"9","key":"pone.0270497.ref023","first-page":"13","article-title":"Efficacy and safety of the combined therapy with citicholine and Actovegin in the acute period of ischemic stroke","volume":"110","author":"N Shamalov","year":"2010","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"2","key":"pone.0270497.ref024","first-page":"21","article-title":"Drug rehabilitation in stroke patients","volume":"107","author":"AA Skoromets","year":"2007","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"Supplement 3","key":"pone.0270497.ref025","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.1016\/j.jval.2019.09.796","article-title":"PCV71. Indirect comparison of neuroprotectors in the treatment of ischemic stroke in the Russian Federation","volume":"22","author":"A Kulikov","year":"2019","journal-title":"Value Health"},{"issue":"7","key":"pone.0270497.ref026","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17116\/jnevro201911907160","article-title":"Pharmacoeconomic analysis of the neuroprotective medicines in the treatment of ischemic stroke","volume":"119","author":"RI Yagudina","year":"2019","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"key":"pone.0270497.ref027","unstructured":"IQVIA facts\u20142019 and 2018 reports. Moscow (Russia): IQVIA; 2021 [Internet]. [cited 6 October 2021]. Available from: https:\/\/www.iqvia.com\/locations\/russia\/publications\/iqvia-facts-archives."},{"key":"pone.0270497.ref028","article-title":"Unified information system in the field of procurement","author":"Russian Federation","year":"2021"},{"key":"pone.0270497.ref029","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"key":"pone.0270497.ref030","article-title":"Bureau of National Statistics of the Agency for Strategic Planning and Reforms of the Republic of Kazakhstan.[","year":"2022","journal-title":"Stat Gov"},{"issue":"2","key":"pone.0270497.ref031","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3233\/JAD-170991","article-title":"The Alzheimer\u2019s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): modifications and responsiveness in pre-dementia populations. A narrative review","volume":"63","author":"JK Kueper","year":"2018","journal-title":"J Alzheimers Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T23:58:54Z","timestamp":1700783934000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0270497"}},"subtitle":[],"editor":[{"given":"Richard","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0270497","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]}}}